Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Methotrexate is an immunosuppressive agent used for the management of ocular inflammatory diseases and rheumatic diseases. Despite its use for ocular inflammation, including uveitis, since 1965, the exact efficacy of methotrexate has not been confirmed by a randomized clinical trial thus far. Our review of previous data of treatment outcomes suggested that methotrexate is moderately effective in suppressing ocular inflammation and decreasing corticosteroid use. In addition, methotrexate is relatively safe and well tolerated by most patients and is the most widely used immunosuppressive drug for the treatment of uveitis in children. In addition to systemic administration of the drug, intraocular administration of methotrexate can be a promising treatment option for uveitis.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi